Literature DB >> 2601797

Use of Permcath (Quinton) catheter in uraemic patients in whom the creation of conventional vascular access for haemodialysis is difficult.

T Pourchez1, P Morinière, A Fournier, J Pietri.   

Abstract

During the last 4 years, the Permcath Quinton double-lumen silicone catheter was inserted into the internal jugular vein of 57 uraemic patients with difficulty for creating conventional vascular access for haemodialysis. In 4 patients, with definitive contraindication of conventional vascular access, this catheter still permits haemodialysis after a duration of 8-25 months. In 25 further patients with terminal uraemia, but poor vein system, it allowed the maturation of an arteriovenous fistula after 2-14 months of use. In 17 patients already on chronic haemodialysis, but who lost abruptly their vascular access (15 grafts and 2 arteriovenous fistulae), it allowed a new arteriovenous fistula to mature in 16 cases after a mean duration of 7.3 +/- months. In 5 patients with short life expectancy because of neoplasia, it allowed to dialyse them until their death which occurred after 6.5 +/- 2.2 months. In 6 patients with acute renal failure and haemostasis problems, it allowed to perform not only dialysis, but also plasmapheresis in 3 and parenteral nutrition in 3 other cases. The complications were the following: sepsis (n = 3); episodes of hypocoagulability due to inadvertent injection of heparin stored in the lumen (n = 2), thrombosis of the lumen (n = 3), and insufficient flow (n = 6). In no case these complications prevented continuation of haemodialysis. The catheter had to be removed in 2 cases because of septis and in 1 case because of insufficient flow. In 3 cases the catheter had to be replaced because of thrombosis and in 1 case because of laceration. These complication rates are, however, fewer than those reported in the literature for arteriovenous shunts or rigid subclavian and femoral catheters. The Permcath catheter seems, therefore to be the method of choice for immediated vascular access in patients in whom the creation of conventional vascular access is difficult.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2601797     DOI: 10.1159/000185771

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  Prevention of recurrent central venous catheter infections with a novel flush solution in a patient on long-term hemodialysis.

Authors:  K J Sheth; K J Henrickson
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

3.  Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients.

Authors:  Maurizio Bossola; Maurizio Sanguinetti; Donata Scribano; Cecilia Zuppi; Stefania Giungi; Giovanna Luciani; Riccardo Torelli; Brunella Posteraro; Giovanni Fadda; Luigi Tazza
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

4.  A prospective evaluation of plasma-TFE and expanded PTFE grafts for routine and early use as vascular access during hemodialysis.

Authors:  T S Helling; P W Nelson; L Shelton
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

Review 5.  Biofilms in periprosthetic orthopedic infections.

Authors:  Stephen J McConoughey; Rob Howlin; Jeff F Granger; Maurice M Manring; Jason H Calhoun; Mark Shirtliff; Sandeep Kathju; Paul Stoodley
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

6.  Treatment guidelines for dialysis catheter-related bacteremia: an update.

Authors:  Michael Allon
Journal:  Am J Kidney Dis       Date:  2009-07       Impact factor: 8.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.